Andrea Nolte
Salem, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
De Novo Synthesis of Elastin by Exogenous Delivery of Synthetic Modified mRNA into Skin and Elastin-Deficient Cells.
Journal: Molecular therapy. Nucleic acids
Published: November 23, 2017
RNA-Eluting Surfaces for the Modulation of Gene Expression as A Novel Stent Concept.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 03, 2017
An Atelocollagen Coating for Efficient Local Gene Silencing by Using Small Interfering RNA.
Journal: Molecular therapy. Nucleic acids
Published: August 04, 2016
In Vitro Evaluation of a Novel mRNA-Based Therapeutic Strategy for the Treatment of Patients Suffering from Alpha-1-Antitrypsin Deficiency.
Journal: Nucleic acid therapeutics
Published: July 01, 2015
In vitro Study of a Novel Stent Coating Using Modified CD39 Messenger RNA to Potentially Reduce Stent Angioplasty-Associated Complications.
Journal: PloS one
Published: May 09, 2015
A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3.
Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Published: March 15, 2014
The chance of small interfering RNAs as eligible candidates for a personalized treatment of prostate cancer.
Journal: Current pharmaceutical biotechnology
Published: March 11, 2014
Endotoxins affect diverse biological activity of chitosans in matters of hemocompatibility and cytocompatibility.
Journal: Journal of materials science. Materials in medicine
Published: December 04, 2013
New basic approach to treat non-small cell lung cancer based on RNA-interference.
Journal: Thoracic cancer
Published: May 01, 2013
New aspects of gene-silencing for the treatment of cardiovascular diseases.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: March 29, 2013
Small interfering RNA transfection against serum response factor mediates growth inhibition of benign prostatic hyperplasia fibroblasts.
Journal: Nucleic acid therapeutics
Published: January 12, 2013
Last Updated: 09/26/2026